A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential for cardiologists and PCPs!

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

Secondary lymphedema occurs when, after surgery or radiotherapy, the lymphatic system cannot drain interstitial fluid effectively, leading to inflammation and fluid accumulation in the limbs. Previous ...

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug ...

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Anxiety disorders, characterized by an excessive apprehension about real or perceived threats and dysfunctional behaviors aimed at avoiding these threats, are among the most common mental health ...

The other has to do with reducing inflammation. He said there’s also appears to be an effect in the brain, which has GLP-1 receptors, and in the lining of the blood vessels. Some of the most ...

Fortunately, large scale randomised trials with GLP-1RA-based therapies that yield greater weight loss are ongoing and several will report out in the next 1-4 years ... have not been randomly ...

Study of 2.4 million participants reveals potential advantages for cardiometabolic and psychiatric conditions alongside increased risks of gastrointestinal and musculoskeletal issues Study ...